ISSOIRE, France & PETAH TIKVA, Israel--(BUSINESS WIRE)--Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, and DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that they are partnering concerning a global solution for diabetes compliance.
While exhibiting at ATTD – Advanced Technologies and Treatments for Diabetes - in Berlin, BIOCORP and DreaMed Diabetes present the content of their collaboration about diabetes compliance.
Since 2015, BIOCORP has been developing a smart cap for pen injectors newly renamed Mallya® (formerly known with the project name Easylog). The device is now taking an important step forward since attending an introduction to the market by end of H1-2019. For the record, Mallya® automatically captures data (dose, date and time) and sends the information in real time to a companion software thanks to Bluetooth technology, with a very high level of accuracy and repeatability.
For its part, DreaMed Diabetes has developed DreaMed AdvisorTM Pro, a cloud-based digital solution generating insulin delivery recommendations by analyzing information from CGM, self-monitoring blood glucose, and insulin pump data. Applying event-driven adaptive learning, Advisor Pro refines its understanding for each individual and sends recommendation to the healthcare provider on how to optimize a patient’s insulin pump settings for basal rate, carbohydrate ratio and correction factor. DreaMed intends to expand the capabilities of DreaMed Advisor to include decision support tools for healthcare professional treating persons with diabetes under basal or multiple daily injections therapy.
Mallya® is therefore completing the DreaMed Advisor concept by providing data related to insulin injections. Mallya® will be integrated to DreaMed Advisor for basal or multiple daily injections delivery by data collection, analysis and generating recommendation for the healthcare professional and person with diabetes. Mallya will be used in clinical trials of DreaMed during 2019.
“This partnership is a real opportunity for our two companies and especially for final patients since it is a real progress concerning the management of diabetes treatment. This new step is significant for BIOCORP since 2019 is a major year for our connected devices: the launch to market of Mallya® is close and this partnership is one of the numerous milestones that will support our commercial success in the future “, declared Eric Dessertenne, COO of BIOCORP.
" For years, DreaMed Diabetes is dedicated to empowering people with diabetes and their care providers with innovative and person-centric digital treatment decision support technologies in order to improve health and quality of life", said Eran Agmon, DreaMed Diabetes Chief Product Officer. "This partnership will allow us to offer innovative decision support solutions for people with diabetes under basal only or multiple daily injections based on an accurate and reliable insulin dosing information."
ABOUT BIOCORP
Founded in 2004 in Issoire (near Clermont-Ferrand),
France, BIOCORP is a French company specializing in the development and
manufacturing of medical devices and innovative drug delivery systems.
It is listed as ‘Innovative Company’ by the French public investment
bank Bpifrance. With over twenty years of experience and more than 30
manufactured products, BIOCORP is a key player in the industry,
providing drug delivery solutions that meet the evolving needs of
patients. Today, BIOCORP continues to innovate in medical plastics, its
core business, and to market traditional devices (alternative to
aluminum capsules, syringe and vial administration systems) that have
been an important source of recurring income. Its solid expertise and
capacity to innovate have allowed the company to develop new
Internet-connected products, including Easylog, a smart cap for pen
injectors that captures injection data and automatically transmits data
to a mobile app, helping patients to manage their treatment. The company
has a team of 45 employees. BIOCORP is listed on Alternext since July
2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
Follow
us on Twitter @BIOCORPSystems
ABOUT DREAMED
DreaMed spun out of Schneider Children’s Medical
Center in 2014, following seven years developing its artificial pancreas
technology. Since then, DreaMed Diabetes develops solutions and
personalized decision support solutions for the optimization of insulin
therapy for people with Type 1 and Type 2 diabetes. The Company’s first
product, GlucoSitter, was developed for closed-loop insulin therapy and
was licensed to Medtronic Diabetes. The Company then developed Advisor,
a portfolio of decision support solutions for patients and healthcare
providers dedicated to transform dynamic, real-world patient data into
actionable treatment insights with its unique, cloud-based cognitive
technology. Investors in the Company include Medtronic Diabetes, Norma
Investments and OurCrowd. For more information, please visit https://ww.dreamed-diabetes.com
